Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Laurus Labs Ltd. ( (IN:LAURUSLABS) ) has provided an announcement.
Laurus Labs Limited has announced that its trading window for dealing in the company’s securities will be closed from April 1, 2026, until 48 hours after the declaration of its audited financial results for the quarter and year ended March 31, 2026. The restriction applies to designated persons, their immediate relatives, and other connected persons, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code, with the board meeting date for approving these results to be communicated later.
The move reflects standard corporate governance and compliance practice aimed at preventing insider trading around the release of key financial information. For investors and other stakeholders, it signals that the company is preparing to finalize and disclose its annual and quarterly audited results, a period that typically brings greater scrutiny of financial performance and outlook.
More about Laurus Labs Ltd.
Laurus Labs Limited is an Indian pharmaceutical company focused on active pharmaceutical ingredients, formulations, and contract research and manufacturing services. The company serves global generic and branded markets, with its shares listed on both BSE and the National Stock Exchange of India under the code LAURUSLABS.
Average Trading Volume: 96,767
Technical Sentiment Signal: Buy
Current Market Cap: 544.9B INR
For detailed information about LAURUSLABS stock, go to TipRanks’ Stock Analysis page.